Skip to main content

Table 1 Clinicopathological characteristics of breast cancer patients (n = 144)

From: Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival

Variable

Total (n%)

Age (Years)

 

Mean ± SD

51.61 ± 11.59

Range

28–82

Breast cancer molecular subtype

 

HER2-enriched

42 (29.2)

Luminal A

31 (21.5)

Triple positive

36 (25.0)

Triple negative (TNBC)

35 (24.3)

Grade

 

I

7 (4.9)

II

35 (24.3)

III

102 (70.8)

Tumor volume (cm 3 )

 

Mean ± SD

41.00 ± 70.88

Range

0.11-571.77

TNM Stage

 

I

7 (4.9)

II

37 (25.7)

III

48 (33.3)

IV

49 (34.0)

Undetermined

3 (2.1)

pT

 

T1

11 (7.6)

T2

74 (51.4)

T3

44 (30.6)

T4

15 (10.4)

pT

 

T1/T2

85 (59.0)

T3/T4

59 (41.0)

pN

 

N0

40 (27.8)

N1

31 (21.5)

N2

29 (20.1)

N3

39 (27.1)

Undetermined

5 (3.5)

M

 

M0

92 (63.9)

M1

49 (34.0)

Undetermined

3 (2.1)

Axillary lymph node metastasis

 

Negative

41 (28.5)

Positive

101 (70.1)

Undetermined

2 (1.4)

Lymphatic/vascular invasion

 

Negative

47 (32.6)

Positive

91 (63.2)

Undetermined

6 (4.2)

HR status

 

Negative

77 (53.5)

Positive

67 (46.5)

HER-2 status

 

Negative

66 (45.8)

Positive

78 (54.2)

DCIS

 

Absent

32 (22.2)

Present

109 (75.7)

Undetermined

3 (2.1)

Family history

 

No

90 (62.5)

Yes

25 (17.4)

Undetermined

29 (20.1)

SP

 

Low (TS ≤ 5)

85 (59.0)

High (TS > 5)

59 (41.0)

NK1R

 

Low (TS ≤ 1)

91 (63.2)

High (TS > 1)

53 (36.8)

Ki-67

 

Low (≤ 22%)

83 (57.6)

High (> 22%)

61 (42.2)

PKM2

 

Low (TS ≤ 4)

78 (54.2)

High (TS > 4)

55 (38.2)

Undetermined

11 (7.6)

  1. SD: standard deviation, HR: hormone receptor, HER2: human epidermal growth factor receptor 2, DCIS: ductal carcinoma in situ, SP: substance P, TS: total score, NK1R: neurokinin 1 receptor, PKM2: pyruvate kinase M2